期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴乳腺癌的中西医治疗进展 被引量：5

下载PDF
导出
摘要 三阴性乳腺癌（triple negative breast cancer，TN-BC）是2006年由Bryan等首次明确提出的，指雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体（HER-2）均阴性的一类乳腺癌，具有恶性程度高、复发转移快、病死率高、治疗手段有限等特点。在临床上TNBC被作为一种难治性乳腺癌看待，而其发病率在乳腺癌患者中有近1／4，因此了解TNBC的治疗进展对于临床乳腺癌的诊治能有很大帮助。
作者 杨锌 张喜平 欧敬民
机构地区 浙江中医药大学 浙江省肿瘤医院乳腺外科 上海交通大学医学院附属新华医院普外科
出处 《医学研究杂志》 2012年第9期188-190,共3页 Journal of Medical Research
关键词 三阴乳腺癌 中西医治疗 人表皮生长因子受体 三阴性乳腺癌 雌激素受体 孕激素受体 乳腺癌患者 恶性程度
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Bryan BB, Schnitt S J, Collins LC. Ductal carcinoma in situ with basal - like phenotype : a possible precursor to invasive basal - like breast cancer[ J]. Mod Pathol,2006,19(5) :617 -621.
  • 2袁中玉,王树森,高岩,苏争艳,罗文标,管忠震.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008,27(6):561-565. 被引量：161
  • 3Reis - Filho JS, Tutt AN. Triple negative tumors: a critical review [ J ]. Histopathology,2008, 52 ( 1 ) : 108 - 118.
  • 4Nielsen TO, Hsu FD, Jensen K,et al. Immunohistochemical and clinical charaterization of the basal - like subtype of invasive breast carcinoma[ J]. Clin Cancer Res,2004,10(16) :5367 - 5374.
  • 5Sasa M, Bando Y, Takahashi M ,et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple negative breast cancer[ J]. J Surg Oncol, 2008,97 (1) :30 -34.
  • 6Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR2 targeted therapies [ J ]. Breast,2007,16 ( 1 ) : 111 - 112.
  • 7Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy [ J]. Breast Cancer Res, 2011,13(2) :R35.
  • 8汪小浪,余锋,易军,熊建萍.初治“三阴”性复发转移性乳腺癌化疗疗效回顾性分析[J].中国肿瘤临床与康复,2008,15(6):522-524. 被引量：1
  • 9王丽萍,王果,周宏灏.表皮生长因子受体多态性对酪氨酸激酶抑制剂药效学影响的研究进展[J].中国临床药理学与治疗学,2010,15(8):938-944. 被引量：3
  • 10Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinic pathological features and gene - expression subtypes of breast cancer [ J ]. Genes Chromosomes Cancer. 2006,45 ( 11 ) : 1033 - 1040.

二级参考文献62

  • 1吴健虹,谢秋玲,陈小佳,洪岸.表皮生长因子受体EGFR及其信号传导[J].生命科学,2006,18(2):116-122. 被引量：40
  • 2Bundred NJ. Prognostic and predictive factors in breast [ J ]. Cancer Treat Rev, 2001, 27 ( 3 ) : 137-142.
  • 3Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : A population-based study from the California Cancer Registry[Jl. Cancer, 2007, 3:20-23.
  • 4Rakha EA, E1-Sayed ME, Green AR. Prognostic markers in triple-negative breast cancer[ J]. Cancer, 2007, 109( 1 ) :25.
  • 5Carey LA, Claim Dees E, Sawyer L, et al. The triple negative paradox : primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007, 13(8) :2329.
  • 6Tsao MS, Sakurada A, Cutz JC,et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome[J]. N EnglJ Med,2005,353(2):133--146.
  • 7Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorareassociatedwith improved survival in gefitinib-treated chemorefraetory lung adenocarcinomas[J]. Clin Cancer Res,2005,11 (16) :5878--5886.
  • 8Shigematsu H, Li L, Takao T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer I, 2005, 97(5) :339--347.
  • 9Kosaka T, Yatabe Y, Endoh Y,et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004,64(24) :8919- 8923.
  • 10Paez JG, Pasi AJ, Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004,304(5676) : 1497 --1450.

共引文献162

同被引文献43

  • 1原发性乳腺癌规范化诊疗指南(试行)[J].中国医学前沿杂志（电子版）,2013,5(5):30-37. 被引量：42
  • 2Bleicher R J, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer[J]. J Clin Oncol,2012,30(36) :4485-4492.
  • 3Eralp Y,Ozluk DD, Yavuz E,et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple- negative breast cancer[J].Ann Oncol,2008,19(4) : 669-674.
  • 4Umemura S,Yoshida S,Ohta Y,et al. Increased phosphoryl- ation of Akt in triple-negative breast cancer[J]. Cancer Sci, 2007,98(12): 1889-1892.
  • 5Parikh RR, Yang Q, Higgins SA, et al. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CKI9 expression[J]. Int J Radiat Oncol Biol Phys,2008,70(1):35-42.
  • 6Kashiwagi S, Yashiro M,Takashima T,et al. Significance of E-cadherin expression in triple-negative breast cancer[J]. Br J Cancer, 2010,103 : 249-255.
  • 7Weng YR,Cui Y,Fang JY. Biological functions of cytokeratin 18 in cancer[J]. Mol Cancer Res,2012,10(4):485-493.
  • 8Shetty S,Gokut S. Keratinization and its disorders[J]. Oman Med J,2012,27(5) :348-357.
  • 9Strnad P, Paschke S, Jang KH, et al. Keratins: markers and modulators of liver disease [J]. Curr Opin Gastroenterol, 2012,28(3) : 209-216.
  • 10Zheng S,Guo Y,Mones JM. Basal cell carcinoma with myoep- ithelial differentiation[J]. Am J Dermatopathol, 2011,33 (8) : 863-866.

引证文献5

二级引证文献27

医学研究杂志
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部